{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:20Z","timestamp":1790286920911,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","rheumatic.theclinics.com","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rdc.2024.01.007","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T21:08:02Z","timestamp":1708722482000},"page":"301-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["De novo Connective Tissue Disorders as Immune-related Adverse Events"],"prefix":"10.1016","volume":"50","author":[{"given":"Lindsay Kristin","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.007_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.007_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.007_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s40674-019-00131-z","article-title":"Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments","volume":"5","author":"Ye","year":"2019","journal-title":"Curr Treat Options Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.007_bib5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/life13040877","article-title":"Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study","volume":"13","author":"Ceccarelli","year":"2023","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.007_bib6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.55563\/clinexprheumatol\/o5nvgv","article-title":"Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre","volume":"39","author":"Gonzalez-Maz\u00f3n","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.190084","article-title":"Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist","volume":"47","author":"Jamal","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.007_bib8","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1136\/annrheumdis-2019-215819","article-title":"Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?","volume":"80","author":"Raschi","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.007_bib10","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2018-213677","article-title":"Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1","volume":"78","author":"Michot","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.007_bib11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bjd.17245","article-title":"Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy","volume":"181","author":"Marano","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib12","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1093\/rheumatology\/keaa389","article-title":"Systemic lupus erythematosus onset in patient receiving anti-PD1 treatment with pembrolizumab: a case report","volume":"60","author":"Ceccarelli","year":"2021","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib13","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/ajd.12681","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab","volume":"59","author":"Liu","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cup.13059","article-title":"Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy","volume":"45","author":"Shao","year":"2018","journal-title":"J\u00a0Cutan Pathol"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.007_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020960967","article-title":"Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy","volume":"10","author":"Glick","year":"2020","journal-title":"Pulm Circ"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib16","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1093\/rheumatology\/keab670","article-title":"Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitor","volume":"61","author":"Takeda","year":"2022","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CMR.0000000000000536","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review","volume":"29","author":"Zitouni","year":"2019","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.007_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.pneumo.2017.08.012","article-title":"[Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases]","volume":"73","author":"de Chabot","year":"2017","journal-title":"Rev Pneumol Clin"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.007_bib19","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1136\/annrheumdis-2018-213470","article-title":"Checkpoint inhibitor-associated immune arthritis","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2024.01.007_bib20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.rdc.2024.01.007_bib21","first-page":"34","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"9","key":"10.1016\/j.rdc.2024.01.007_bib22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.007_bib23","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2024.01.007_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fimmu.2014.00206","article-title":"Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1","volume":"5","author":"Kong","year":"2014","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.007_bib25","doi-asserted-by":"crossref","first-page":"9794","DOI":"10.3390\/ijms16059794","article-title":"Association between PDCD1 Gene Polymorphisms and Risk of Systemic Lupus Erythematosus in Three Main Ethnic Groups of the Malaysian Population","volume":"16","author":"Chua","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.007_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s10875-006-9048-9","article-title":"Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan","volume":"26","author":"Wang","year":"2006","journal-title":"J\u00a0Clin Immunol"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.007_bib27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng1020","article-title":"A\u00a0regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans","volume":"32","author":"Prokunina","year":"2002","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.rdc.2024.01.007_bib28","doi-asserted-by":"crossref","first-page":"36885","DOI":"10.18632\/oncotarget.16378","article-title":"Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.rdc.2024.01.007_bib29","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2005-06-2298","article-title":"Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti\u2013CTLA-4 antibodies","volume":"106","author":"Lute","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.007_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic Reactions to Immune Checkpoint Inhibitors","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.007_bib31","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma Induced by Pembrolizumab: A Case Series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.rdc.2024.01.007_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-244968","article-title":"Atezolizumab-induced scleroderma: a rare complication","volume":"14","author":"Grant","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.rdc.2024.01.007_bib33","article-title":"Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung","volume":"2022","author":"Dobrzynski","year":"2022","journal-title":"Case Rep Dermatol Med"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.007_bib34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J\u00a0Cutan Pathol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib35","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/1346-8138.14492","article-title":"Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma","volume":"46","author":"Cho","year":"2019","journal-title":"J\u00a0Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/annonc\/mdw543","article-title":"Pembrolizumab induced severe sclerodermoid reaction","volume":"28","author":"Shenoy","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.007_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.007_bib38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.007_bib39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib40","first-page":"259","article-title":"Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics","volume":"16","author":"Macklin","year":"2023","journal-title":"Pharm Basel Switz"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000525887","article-title":"Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management","volume":"14","author":"Fattore","year":"2022","journal-title":"Case Rep Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.007_bib42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/art.20056","article-title":"PM-Scl-75 is the main autoantigen in patients with the polymyositis\/scleroderma overlap syndrome","volume":"50","author":"Raijmakers","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12885-019-5661-x","article-title":"Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review","volume":"19","author":"Khaddour","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-018-0321-2","article-title":"Ipilimumab induced digital vasculitis","volume":"6","author":"Padda","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.007_bib45","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1634\/theoncologist.2019-0666","article-title":"Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor\u2013Induced Raynaud\u2019s-Like Phenomenon","volume":"25","author":"Khan","year":"2020","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12885-017-3313-6","article-title":"Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade","volume":"17","author":"Gambichler","year":"2017","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.rdc.2024.01.007_bib47","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2022.07.004","article-title":"Tumor-Associated Raynaud\u2019s Phenomenon Exacerbated by Administration of Immune Checkpoint Inhibitors","volume":"17","author":"Sumi","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.007_bib48","article-title":"Acral vascular syndrome during an immune checkpoint inhibitor","volume":"13","author":"O\u2019Connor","year":"2020","journal-title":"BMJ Case Rep CP"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib49","first-page":"106","article-title":"A\u00a0severe and rare immune-related toxicity associated with a complete response to combination immunotherapy for metastatic melanoma\u2013a case report of acral vascular syndrome","volume":"2","author":"Krishnan","year":"2021","journal-title":"J\u00a0Case Rep Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40425-018-0443-6","article-title":"Immune checkpoint inhibitor-related acral vasculitis","volume":"6","author":"Comont","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10","key":"10.1016\/j.rdc.2024.01.007_bib51","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JOP.19.00333","article-title":"Raynaud\u2019s Phenomenon From PD-1 Immune Checkpoint Inhibition","volume":"16","author":"Kim","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.rdc.2024.01.007_bib52","series-title":"The Journal of rheumatology","first-page":"1051","article-title":"Acral Digital Ischemia Associated with Immune Checkpoint Inhibitor Therapy: A Case Series of the Canadian Research Group of Rheumatology in Immuno-Oncology (CANRIO) experience","volume":"50","author":"Himmel","year":"2020"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1067\/mjd.2002.120474","article-title":"Paraneoplastic acral vascular syndrome: Epidemiologic features, clinical manifestations, and disease sequelae","volume":"47","author":"Poszepczynska-Guign\u00e9","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2024.01.007_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.rdc.2024.01.007_bib55","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rdc.2024.01.007_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02053","article-title":"Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis","volume":"11","author":"Thompson","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.007_bib57","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.007_bib58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T19:54:49Z","timestamp":1713988489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X24000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0889857X24000073"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2024.01.007","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De novo Connective Tissue Disorders as Immune-related Adverse Events","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2024.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}